Oncternal Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update

Rhea-AI Summary

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) will announce its Q1 2021 financial results post-market on May 6, 2021. A webcast led by management will follow at 2:00 PM PT (5:00 PM ET) to discuss the results and provide a business update. Oncternal focuses on developing oncology therapies for critical medical needs, with ongoing clinical trials for cirmtuzumab and TK216. The company's pipeline targets significant cancer pathways, including a combination therapy for mantle cell lymphoma and a targeted inhibitor for Ewing sarcoma.

Positive

• Ongoing clinical trials for innovative therapies targeting critical cancer pathways.
• Focus on unmet medical needs in oncology may drive future growth.

Negative

• None.

SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2021 financial results after the U.S. financial markets close on Thursday, May 6, 2021. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the Company’s financial results and provide a comprehensive business update.

The live webcast of the call will be available online via a link from the investor relations page of the Company’s website at www.oncternal.com, and the call will be archived there for at least 30 days.  

About Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. The clinical pipeline also includes TK216, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program utilizing the cirmtuzumab antibody backbone to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. More information is available at www.oncternal.com.

Oncternal Contacts:

Company Contact
Richard Vincent
858-434-1113
rvincent@oncternal.com

Investor Contact
Corey Davis, Ph.D.         
LifeSci Advisors         
212-915-2577                 
cdavis@lifesciadvisors.com

Source: Oncternal Therapeutics, Inc.

FAQ

When will Oncternal report its Q1 2021 financial results?

Oncternal will report its Q1 2021 financial results on May 6, 2021, after market close.

What therapies is Oncternal currently developing?

Oncternal is developing cirmtuzumab and TK216, targeting different cancer pathways.

What time is Oncternal's financial results webcast?

The webcast for Oncternal's financial results will be held at 2:00 PM PT (5:00 PM ET) on May 6, 2021.